

**Drug Pricing**

**Publication:** Mint (Similar reports in The Hindustan Times, Deccan Chronicle, The Financial Express, The Telegraph, The Hindu Business Line, The New Indian Express)

**Edition:** Online

**Date:** December 11, 2013

**Headline:** [Revised lower price of drugs will be effective immediately: SC](#)

**Synopsis:** In good news for consumers, the Supreme Court has held that an order reducing prices of particular medicines will come into force with immediate effect after its publication in the gazette and firms should implement it within 15 days time and not sell unsold stocks at higher price.

A bench of justices R M Lodha and Kurian Joseph dismissed the appeals preferred by medicines firms and the distributors seeking the order that the stocks cleared by the manufacturer before the 15th day can be allowed to sold to consumers at the higher unrevised price.

**Publication:** Business Standard

**Edition:** National

**Date:** December 11, 2013

**Headline:** [New pricing policy to hit pharma growth a tad](#)

**Synopsis:** The recent policy implemented by the National Pharmaceutical Pricing Authority (NPPA) will hit the revenue of domestic companies in the sector marginally this financial year. According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13. However, top companies are optimistic about bouncing back from the revenue losses and are expecting better revenue growth in the next couple of quarters. Of the top 10 companies, which generated 31 per cent of the Rs 72,000-crore Indian pharma market, the growth for five — Sun Pharma, Cipla, Lupin, Dr Reddy's and Merck Ltd — was more than the market growth.

**FDI**

**Publication:** The Economic Times

**Edition:** National

**Date:** December 11, 2013

**Headline:** [RBI seeks clarity on FII investment in pharmaceutical sector](#)

**Synopsis:** The Reserve Bank (RBI) has sought clarity on whether foreign portfolio investments can be allowed in existing companies without government approval, putting the spotlight back on a sector that has been the subject of much debate and policy change with respect to overseas investment.

The current policy for the pharma sector allows foreign direct investment (FDI) up to 100% through the automatic route in greenfield units, but investment in existing companies needs the approval of the Foreign Investment Promotion Board (FIPB).

**Patents**

**Publication:** The Hindu Business Line

**Edition:** National

**Date:** December 11, 2013

**Headline:** [No clarity on pricing, patents'](#)

**Synopsis:** The Hindu Business Line published an interview with Pfizer India chief, Aijaz Tobaccowalla, on

prospects and pitfalls of doing business in India. Aijaz spoke about the company's products, industry issues such as patents, pricing, clinical trials, access etc.

## Innovation

**Publication: The Hindu Business Line**

**Edition: National**

**Date: December 11, 2013**

**Headline: [No one has a recipe for innovation'](#)**

**Synopsis:** In an interview with The Hindu Business Line, Hugh Durrant Whyte, CEO, National ICT Australia (NICTA) spoke R&D and IP creation. He is of the opinion that although Indian companies are focussing on R&D, they are still business focussed. They must recognise that putting more money into research will make them more competitive. On IP creation he said, one needs to be patient. Indian companies have done an excellent job in creating reputation for delivery, for value and now is the time when may be whole innovation will start to increase. This is exactly why we are here and how to be part of that. No one has a recipe for innovation. There is no such thing.

**Publication: The Hindustan Times**

**Edition: National**

**Date: December 11, 2013**

**Headline: [Looking for innovative answers to global healthcare issues, leaders gather in Doha](#)**

**Synopsis:** Hundreds of policymakers and medical experts from 67 countries gathered at Doha in Qatar on Tuesday for the World Innovation Summit for Health (WISH). Seeking innovative solutions to the world's biggest healthcare challenges, the two-day summit will also have celebrated leaders like Daw Aung San Suu Kyi – chairperson of Myanmar's National League for Democracy.

"Innovation is the answer" – said Lord Darzi of Denham in the UK, chairman of the Institute of Global Health Innovation at Imperial College London and executive chair of WISH, at the inaugural session on Tuesday.

"We must embrace the innovation we need to secure the health we want, whoever we are and wherever we live."

The conference is being hosted by the Qatar Foundation for Education, Science and Community Development – which has Her Highness Sheikha Moza bint Nasser of Qatar as its chairperson.

## Clinical Trials

**Publication: Pharmabiz**

**Edition: National**

**Date: December 11, 2013**

**Headline: [54 deaths reported during clinical trials in three years from 2010: Minister](#)**

**Synopsis:** The Union health ministry has said that total number of deaths related to clinical trials during three years from 2010 were 54 while the casualties and injuries during the year of 2013 were still to be assessed. In a written reply in the Lok Sabha recently, Health Minister Ghulam Nabi Azad said the number of deaths related to clinical trials in the year 2010, 2011 and 2012 were 22, 16 and 16 respectively as per the available data. "The reports of Serious Adverse Events (SAEs) of injuries and deaths, received in the current year 2013 are under examination. Compensations have been paid in 21 cases of deaths related to clinical trial in 2010 and in all cases in 2011 and 2012. In one case of 2010, the compensation remained unpaid as whereabouts of the legal heir could not be traced by the investigator and his team in spite of their best efforts," he said.

## General Industry

**Publication: Business Standard**

**Edition: National**

**Date: December 11, 2013**

**Headline: [EU fines Johnson & Johnson, Novartis \\$22 mn](#)**

**Synopsis:** The European Commission fined drugmakers Johnson & Johnson and Novartis a combined 16 million euros or about \$21.95 million Tuesday for delaying market entry of a cheaper generic painkiller in the Netherlands.

**Publication: The Economic Times**

**Edition: National**

**Date: December 11, 2013**

**Headline: [Eli Lilly enters branded generics; launches four cancer drugs](#)**

**Synopsis:** Drug firm Eli Lilly and Company India today said it has entered into branded generics segment in the country with the launch of four cancer drugs to treat patients with breast and colo-rectal cancer respectively. The company said it has entered branded generics segment with launch of Lil Therapeutics, an expansion of its oncology division that will help expand delivery of cancer drugs to patients at an affordable cost, Eli Lilly and Company said in a statement.

**Publication: The Economic Times**

**Edition: National**

**Date: December 11, 2013**

**Headline: [Lupin gets USFDA nod to market HIV drug in the US](#)**

**Synopsis:** Drug major LupinBSE 0.57 % today said it has received US health regulator's approval to market generic version of ViiV Healthcare's Trizivir tablets, used in the treatment of HIV-1 infection, in the American market. The company has received final approval from the US Food and Drug Administration (USFDA) for its Abacavir Sulfate Lamivudine, and Zidovudine Tablets, Lupin Ltd said in a statement. The company's product is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection, it added.

"Lupin was the first applicant to file an abbreviated new drug application (ANDA) for Trizivir tablets and as such will be entitled to 180 days of marketing exclusivity," the company said.

According to IMS MAT September 2013 sales data, Trizivir tablets has US sales of around USD 111.6 million. Lupin's cumulative ANDA filings with the USFDA as of October 30 stands at 183 and the Mumbai-headquartered firm has received 93 approvals to date. During the current year, the company has so far received 17 approvals from USFDA. It has also launched 13 products in the US market in the current year so far.

"Lupin is the market leader in 26 products in the US generic market and is amongst the top three by market share in 40 products out of the overall 57 products in the market," it the company said. Shares of Lupin were trading at Rs 863.70 a piece on the BSE in afternoon trade, up 1.28 per cent from its previous close.